ORMP Logo

Oramed Pharmaceuticals Inc. (ORMP) 

NASDAQ
Market Cap
$95.81M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
658 of 776
Rank in Industry
358 of 433

Largest Insider Buys in Sector

ORMP Stock Price History Chart

ORMP Stock Performance

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a …

Insider Activity of Oramed Pharmaceuticals Inc.

Over the last 12 months, insiders at Oramed Pharmaceuticals Inc. have bought $0 and sold $0 worth of Oramed Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Oramed Pharmaceuticals Inc. have bought $415,102 and sold $1.8M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,800 shares for transaction amount of $8,398 was made by Mayer Arie (director) on 2023‑04‑04.

List of Insider Buy and Sell Transactions, Oramed Pharmaceuticals Inc.

2023-04-04Purchasedirector
3,800
0.01%
$2.21$8,398+30.56%
2023-04-03Purchasedirector
5,009
0.0129%
$2.22$11,120+27.60%
2023-03-16PurchasePresident and CEO
26,000
0.0615%
$2.04$53,014+23.98%
2023-03-14SaleChief Scientific Officer
100,000
0.2466%
$2.01$201,000+28.71%
2023-03-14PurchasePresident and CEO
100,000
0.2466%
$2.01$201,000+28.71%
2023-03-14Purchasedirector
50,000
0.1257%
$2.05$102,450+28.71%
2023-03-13Purchasedirector
20,000
0.0499%
$1.96$39,120+33.83%
2023-01-03SaleChief Commercial Officer
13,325
0.0346%
$12.55$167,195-81.41%
2022-03-21Sale
10,000
0.0258%
$9.41$94,096-28.66%
2021-11-01Saledirector
3,000
0.0084%
$25.60$76,800-65.71%
2021-09-16Saledirector
21,100
0.0579%
$20.99$442,830-55.94%
2021-08-09SalePresident and CEO
220,000
0.7367%
$20.11$4.42M-50.47%
2019-09-09Purchasedirector
50,000
0.2901%
$2.92$146,000+20.49%
2019-07-18Purchasedirector
8,994
0.0501%
$3.85$34,672-15.66%
2019-07-17Purchasedirector
60,040
0.3268%
$3.63$218,118-12.57%
2019-07-16Purchasedirector
40,000
0.2278%
$3.52$140,878-5.65%
2019-07-11Purchasedirector
2,640
0.0147%
$3.22$8,501+1.21%
2018-08-09Purchasedirector
5,000
0.029%
$4.95$24,740-25.77%
2018-07-11PurchasePresident and CEO
244
0.0014%
$5.92$1,444-36.64%
2018-07-10SalePresident and CEO
122
0.0007%
$5.98$730-36.67%

Insider Historical Profitability

22.97%
Bronfeld Zeev10 percent owner
5808517
14.2474%
$2.3511
REGALS CAPITAL MANAGEMENT LP10 percent owner
1453637
3.5655%
$2.3570<0.0001%
Sank Leonarddirector
374999
0.9198%
$2.35120+53.34%
Li Xiaopengdirector
206350
0.5061%
$2.3520+13.29%
KIDRON NADAVPresident and CEO
126000
0.3091%
$2.3572+24.17%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Murchinson Ltd$4.03M3.41.38M+31.38%+$962,125.300.45
Bml Capital Management Llc$2.47M2.08844,496-33.06%-$1.22M1.89
Boothbay Fund Management LLC$2.01M1.7689,749+31.38%+$481,064.140.07
Susquehanna International Group$1.01M0.85344,438+650.15%+$871,684.28<0.01
Rathbone Brothers$846,225.000.71289,8030%+$00.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.